Your session is about to expire
← Back to Search
Monoclonal Antibodies
Cosibelimab + Ublituximab + Bendamustine combination for Non-Hodgkin's Lymphoma
Phase 1
Waitlist Available
Research Sponsored by TG Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new treatment for people whose B-cell Non-Hodgkin's Lymphoma has come back or didn't respond to previous treatments. The treatment uses a drug called cosibelimab alone or combined with two other drugs, ublituximab and bendamustin. These drugs help the immune system fight cancer and directly attack cancer cells.
Eligible Conditions
- Richter's Transformation
- Non-Hodgkin's Lymphoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adverse Events That Are Related to Treatment
Secondary study objectives
Overall Response Rate
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: Cohort CExperimental Treatment1 Intervention
Cosibelimab + Ublituximab + Bendamustine combination
Group II: Cohort BExperimental Treatment1 Intervention
Cosibelimab + Ublituximab + Bendamustine combination
Group III: Cohort AExperimental Treatment1 Intervention
Cosibelimab (TG-1501) single-agent
Find a Location
Who is running the clinical trial?
TG Therapeutics, Inc.Lead Sponsor
39 Previous Clinical Trials
6,840 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger